As in the HER2+ patients, F/B significantly increases in the tumor bulk with NACT administration (5.37 ± 0.34 (biopsy) versus 6.81 ± 0.56 (excision); paired t-test, p = 0.038, Figure 6a), but not in the tumor-stroma interface of TNBC samples (8.18 ± 0.41 (biopsy) versus 8.11 ± 0.35 (excision); paired t-test, p = 0.92, Figure 6b). Here, ERBB2 is linked to neoplasm.